Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 11, 2002 - Issue 4
Submit an article Journal homepage
22
Views
0
CrossRef citations to date
0
Altmetric
Miscellaneous

Pharmaceutical thrombosis prevention in cardiovascular disease

Mats Eriksson †Department of Surgical Sciences, Anesthesiology & Intensive Care, University Hospital, Uppsala, Sweden
,
Kjeld Christensen †Department of Surgical Sciences, Anesthesiology & Intensive Care, University Hospital, Uppsala, Sweden
,
Tomas L Lindahl †Department of Surgical Sciences, Anesthesiology & Intensive Care, University Hospital, Uppsala, Sweden
&
Anders Larsson †Department of Surgical Sciences, Anesthesiology & Intensive Care, University Hospital, Uppsala, Sweden
Pages 553-563 | Published online: 24 Feb 2005

Bibliography

  • ANTIPLATELET TRIALISTS' COLLABORATION: Secondary prevention of vascular disease by prolonged antiplatelet treatment. BMI Pin Res. Ed.) (1988) 296:320–331.
  • ANTIPLATELET TRIALISTS' COLLABORATION: Collaborative overview of randomised trials of antiplatelet therapy--II: Maintenance of vascular graft or arterial patency by antiplatelet therapy. BAH (1994) 308:159–168.
  • ALGRA A, DE SCHRYVER EL, VAN GUN J, KAPPELLE LJ, KOUDSTAAL PJ: Oral anticoagulants versus antiplatelet therapy for preventing further vascular events after transient ischaemic attack or minor stroke of presumed arterial origin (Cochrane Review). Cochrane Database Syst. Rev (2001) 4: CDOO 1342.
  • BENAVENTE 0, HART R, KOUDSTAAL P, LAUPACIS A, MCBRIDE R: Antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks. Cochrane Database Syst. Rev (2000) 2:CD001925.
  • GUBITZ G, SANDERCOCK P, COUNSELL C: Antiplatelet therapy for acute ischaemic stroke. Cochrane Database Syst. Rev (2000) 2:CD000029.
  • ISIS-2 (SECOND INTERNATIONAL STUDY OF INFARCT SURVIVAL) COLLABORATIVE GROUP: Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet (1988) 2:349–360.
  • QUINN M, DEERING A, STEWART M, COX D, FOLEY B, FITZGERALD D: Quantifying GPIIb/IIIa receptor binding using 2 monoclonal antibodies: discriminating abciximab and small molecular weight antagonists. Circulation (1999) 99:2231–2238.
  • SHATTIL SJ, HOXIE JA, CUNNINGHAM M, BRASS LF: Changes in the platelet membrane glycoprotein IIb.IIIa complex during platelet activation. J Biol. Chem. (1985) 260:11107–11114.
  • SHATTIL SJ, LEAVITT AD: All in the family: primary megakaryocytes for studies of platelet alphaIIbbeta3 signaling. Thromb. Haemost. (2001) 86:259–265.
  • PLOW EF, CIERNIEWSKI CS, XIAO Z, HAAS TA, BYZOVA TV: AlphaIIbbeta3 and its antagonism at the new millennium. Thromb. Haemost. (2001) 86:34–40.
  • •Function of GPIIb/IIIa receptor.
  • MONDORO TH, WHITE MM, JENNINGS LK: Active GPIIb-IIIa conformations that link ligand interaction with cytoskeletal reorganization. Blood (2000) 96:2487–2495.
  • PROIMOS G: Platelet aggregation inhibition with glycoprotein IIb--IIIa inhibitors. Thromb. Thrombol (2001) 11:99–110.
  • D'SOUZA SE, GINSBERG MH, BURKE TA, LAM SC, PLOW EF: Localization of an Arg-Gly-Asp recognition site within an integrin adhesion receptor. Science (1988) 242:91–93.
  • •Description of the RGD site.
  • D'SOUZA SE, GINSBERG MH, LAM SC, PLOW EF: Chemical cross-linking of arginyl-glycyl-aspartic acid peptides to an adhesion receptor on platelets. .1 Biol. Chem. (1988) 263:3943–3951.
  • BENNETT JS: Platelet-fibrinogen interactions. Ann. NY Acad. Sci (2001) 936:340–354.
  • •Recent review of fibrinogen-platelet interactions.
  • COLLER BS, ANDERSON K, WEISMAN HF: New antiplatelet agents: platelet GPIIb/ IIIa antagonists. Thromb. Haemost. (1995) 74:302–308.
  • SEYMOUR JL, HENZEL WJ, NEVINS B,STULTS JT, LAZARUS RA: Decorsin. A potent glycoprotein IIb-IIIa antagonist and platelet aggregation inhibitor from the leech Macrobdella decora. Biol. Chem (1990) 265:10143–10147.
  • MARKLAND FS: Snake venoms and the hemostatic system. Toxicon (1998) 36:1749–1800.
  • COLLER BS: Anti-GPIIb/IIIa drugs: currentstrategies and future directions. Thromb. Haemost. (2001) 86:427–443.
  • •Extensive summary of clinical studies with GPIIb/IIIa inhibitors.
  • COLLER BS: Platelet GPIIb/IIIa antagonists: the first anti-integrin receptor therapeutics. Clin. Invest. (1997) 100:S57–S60.
  • STEINHUBL SR, KOTTKE-MARCHANT K, MOLITERNO DJ et al: Attainment and maintenance of platelet inhibition through standard dosing of abciximab in diabetic and nondiabetic patients undergoing percutaneous coronary intervention. Circulation (1999) 100:1977–1982.
  • MASCELLI MA, LANCE ET, DAMARAJU L, WAGNER CL, WEISMAN HF, JORDAN RE: Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GP IIb/IIIa receptor blockade. Circulation (1998) 97:1680–1688.
  • •Pharmacological studies of ReoPro.
  • WAGNER CL, MASCELLI MA, NEBLOCK DS, WEISMAN HF, COLLER BS, JORDAN RE: Analysis of GPIIb/IIIa receptor number by quantification of 7E3 binding to human platelets. Blood (1996) 88:907–914.
  • FAULDS D, SORKIN EM: Abciximab (c7E3 Fab). A review of its pharmacology and therapeutic potential in ischaemic heart disease. Drugs (1994) 48:583–598.
  • •Pharmacological studies of ReoPro.
  • KIM LT, YAMADA KM: The regulation of expression of integrin receptors. Proc. Soc. Exp. Biol. Med. (1997) 214:123–131.
  • KUPATT C, HABAZETTL H, HANUSCH P et al.: c7E3Fab reduces postischemic leukocyte-thrombocyte interaction mediated by fibrinogen. Implications for myocardial reperfusion injury. Arteriosclec Thromb. Vasc. Biol. (2000) 20:2226–2232.
  • NEUMANN FJ, ZOHLNHOFER D, FAKHOURY L, OTT I, GAWAZ M, SCHOMIG A: Effect of glycoprotein IIb/ IIIa receptor blockade on platelet-leukocyte interaction and surface expression of the leukocyte integrin Mac-1 in acute myocardial infarction. Am. Coll .Cardiol (1999) 34:1420–1426.
  • RIDKER PM, STAMPFER MJ, RIFAI N: Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA (2001) 285:2481–2485.
  • RIFAI N, RIDKER PM: High-sensitivity C-reactive protein: a novel and promising marker of coronary heart disease. Clin. Chem. (2001) 47:403–411.
  • WU CH, CHEN YC, HSIAO G, LIN CH, LIU CM, SHEU JR: Mechanisms involved in the inhibition of neointimal hyperplasia by abciximab in a rat model of balloon angioplasty. Thromb. Res. (2001) 101:127–138.
  • Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC Investigation. N Engl. I Med. (1994) 330:956–961.
  • •Results of the EPIC study. Evaluation of ReoPro in conjunction with PCI.
  • LINCOFF AM: GUSTO IV: Expanding therapeutic options in acute coronary syndromes. Am. Heart .1. (2000) 140:S103–5114.
  • MEMON MA, BLANKENSHIP JC, WOOD GC, FREY CM, MENAPACE FJ: Incidence of intracranial hemorrhage complicating treatment with glycoprotein IIb/IIIa receptor inhibitors: a pooled analysis of major clinical trials. Am. Med (2000) 109:213–217.
  • MADAN M, TCHENG JE: Update on Abciximab Readministration During Percutaneous Coronary Interventions. Curt: Interv. Cardiol Rep. (2000) 2:244–249.
  • TCHENG JE: A symposium: safety issuesconcerning the use of glycoprotein IIb-IIIa inhibitors in the management of acute coronary syndromes. Am .Heart .1. (1999) 138:261-262.
  • THE EPILOG INVESTIGATORS: Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl. J. Med (1997) 336:1689–1696.
  • •Clinical study showing that ReoPro improved long-term outcome after PTCA (the EPILOG study).
  • Randomised placebo-controlled and balloon- angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-lib/Ilia blockade. The EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. Lancet (1998) 352:87–92.
  • •Clinical study showing that ReoPro improved long-term outcome after stenting (the EPISTENT study).
  • SIMOONS ML: Effect of glycoprotein IIb/ Ma receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial. Lancet (2001) 357:1915–1924.
  • Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE Study. Lancet (1997) 349:1429–1435.
  • •Improved outcome after treatment of unstable refractory angina with ReoPro (the CAPTURE study).
  • TOPOL EJ, MOLITERNO DJ, HERRIVIANN HC et al: Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl. J. Med. (2001) 344:1888–1894.
  • DOGGRELL SA: ReoPro rules: results from the 'Do Tirofiban and ReoPro Give Similar Efficacy Trial (TARGET). Expert Opin. Pharmacother. (2001) 2:1507–1509.
  • KLEIMAN NS: GP IIb/IIIa antagonists. Clinical experience and potential uses in cardiology. Drugs R&D (1999) 1:361–370.
  • MCCLELLAN KJ, GOA KL: Tirofiban. A review of its use in acute coronary syndromes. Drugs (1998) 56:1067–1080.
  • •Pharmacological review of tirofiban.
  • BEDNAR B, COOK JJ, HOLAHAN MA et al.: Fibrinogen receptor antagonist-induced thrombocytopenia in chimpanzee and rhesus monkey associated with preexisting drug-dependent antibodies to platelet glycoprotein IIb/IIIa. Blood(1999) 94:587–599.
  • PLATELET RECEPTOR INHIBITION IN ISCHEMIC SYNDROME MANAGEMENT IN PATIENTS LIMITED BY UNSTABLE SIGNS AND SYMPTOMS (PRISM-PLUS) STUDY INVESTIGATORS: Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl. j Med. (1998) 338:1488–1497.
  • •Aggrastat reduces the number of deaths or MI in patients with unstable angina (the PRISM-PLUS study).
  • GIBSON CM, GOEL M, COHEN DJ et al.: Six-month angiographic and clinical follow-up of patients prospectively randomized to receive either tirofiban or placebo during angioplasty in the RESTORE trial. Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis. Am. Coll Cardiol. (1998) 32:28–34.
  • A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators. N Engl. J. Med. (1998) 338:1498–1505.
  • •Treatment of patients with unstable angina with tirofiban reduced the incidence of death, MI and ischaemia (the PRISM study).
  • ALEXANDER JH, HARRINGTON RA: Recent antiplatelet drug trials in the acute coronary syndromes. Clinical interpretation of PRISM, PRISM-PLUS, PARAGON A and PURSUIT. Drugs (1998) 56:965–976.
  • THEL MC, CALIFF RM, TARDIFF BE et al.: Timing of and risk factors for myocardial ischemic events after percutaneous coronary intervention (IMPACT-II). Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis. Am. J. Cardiol (2000) 85:427–434.
  • •One of the studies that led to the FDA approval for eptifibatide in PCI.
  • THE PURSUIT (PLATELET GLYCOPROTEIN IIB/IIIA IN UNSTABLE ANGINA: RECEPTOR SUPPRESSION USING INTEGRILIN THERAPY) TRIAL INVESTIGATORS: Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl. J .Med. (1998) 339:436–443.
  • •One of the studies that led to the FDA approval for eptifibatide in PCI.
  • Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial. Lancet (2000) 356:2037–2044.
  • HASDAI D, HARRINGTON RA, HOCHMAN JS et al.: Platelet glycoprotein IIb/IIIa blockade and outcome of cardiogenic shock complicating acute coronary syndromes without persistent ST-segment elevation. J. Am. Coll. Cardiol (2000) 36:685–692.
  • Combining thrombolysis with the plateletglycoprotein IIb/IIIa inhibitor lamifiban: results of the Platelet Aggregation Receptor Antagonist Dose Investigation and Reperfusion Gain in Myocardial Infarction (PARADIGM) trial.' Am. Coll. Cardiol. (1998) 32: 2003-2010.
  • DOOLEY M, GOA KL: Lamifiban. Drugs(1999) 57:215–221.
  • NEWBY LK, OHMAN EM, CHRISTENSON RH et al.: Benefit of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes and troponin t-positive status: the paragon-B troponin T substudy. Circulation (2001) 103:2891–2896.
  • O'NEILL WW, SERRUYS P, KNUDTSON M et al.: Long-term treatment with a platelet glycoprotein-receptor antagonist after percutaneous coronary revascularization. EXCITE Trial Investigators. Evaluation of Oral Xemilofiban in Controlling Thrombotic Events. N Engl. J. Med. (2000) 342:1316–1324.
  • CANNON CP, MCCABE CH, WILCOX RG et al.: Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial. Circulation (2000) 102:149–156.
  • THE SYMPHONY INVESTIGATORS. SIBRAFIBAN VERSUS ASPIRIN TO YIELD MAXIMUM PROTECTION FROM ISCHEMIC HEART EVENTS POST-ACUTE CORONARY SYNDROMES: Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: a randomised trial. Lancet (2000) 355:337–345.
  • STOREY RF, NEWBY LJ, HEPTINSTALL S: Effects of P2Y1 and P2Y12 receptor antagonists on platelet aggregation induced by different agonists in human whole blood. Platelets (2001) 12:443–447.
  • STOREY RF: The P21'12 receptor as a therapeutic target in cardiovascular disease. Platelets (2001) 12:197–209.
  • BERTRAND ME, RUPPRECHT HJ, URBAN P, GERSHLICK AH, INVESTIGATORS F: Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting : the clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation (2000) 102:624–629.
  • SAVI P, LABOURET C, DELESQUE N, GUETTE F, LUPKER J, HERBERT JM: P2y(12), a new platelet ADP receptor, target of clopidogrel. Biochem. Biophys. Res. Commun. (2001) 283:379–383.
  • HARKER LA, MARZEC UM, KELLY AB et al.: Clopidogrel inhibition of stent, graft, and vascular thrombogenesis with antithrombotic enhancement by aspirin in nonhuman primates. Circulation (1998) 98:2461–2469.
  • HERBERT JM, BERNAT A, MAFFRAND JP: Importance of platelets in experimental venous thrombosis in the rat. Blood (1992) 80:2281–2286.
  • A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet (1996) 348:1329–1339.
  • MEHTA SR, YUSUF S, PETERS RJ et al: Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet (2001) 358:527–533.
  • YUSUF S, ZHAO F, MEHTA SR, CHROLAVICIUS S, TOGNONI G, FOX KK: Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl. J. Med. (2001) 345:494–502.
  • •This study shows that clopidogrel has beneficial effects in patients with acute coronary syndromes without ST-segment elevation.
  • LEYS D: Atherothrombosis: a major health burden. Cerebrovasc. Dis. (2001) 11 (Suppl. 2):1–4.
  • BOGOUSSLAVSKY J: Benefit of ADP receptor antagonists in atherothrombotic patients: new evidence. Cerebrovasc. Dis. (2001) 11\(Suppl. 2):5–10.
  • STOREY RE SANDERSON HM, WHITE AE, MAY JA, CAMERON KE, HEPTINSTALL S: The central role of the P(2T) receptor in amplification of human platelet activation, aggregation, secretion and procoagulant activity. Br. J. Haematol (2000) 110:925–934.
  • STOREY RF, OLDROYD KG, WILCOX RG: Open multicentre study of the P2T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes. Thromb. Haemost. (2001) 85:401–407.
  • SANDERSON PE: Small, noncovalent serine protease inhibitors. Med. Res. Rev (1999) 19:179–197.
  • MAY RD, HAWKESWOOD E, POWLING MJ: Superior efficacy of low molecular weight thrombin inhibitors in a novel M vitro model of clot bound thrombin. Blood (1994) 84:273-273a.
  • CLOSE P, BICHLERJ, KERRY R et al.: Weak allergenicity of recombinant hirudin CGP 39393 (REVASC) in immunocompetent volunteers. The European Hirudin in Thrombosis Group (HIT Group). Coron. Artery Dis. (1994) 5:943–949.
  • STEINMETZER T, HAUPTMANN J, STURZEBECHER J: Advances in the development of thrombin inhibitors. Expert Opin. Investig. Drugs (2001) 10:845–864.
  • GUSTAFSSON D, ANTONSSON T, BYLUND R et al.: Effects of melagatran, a new low-molecular-weight thrombin inhibitor, on thrombin and fibrinolytic enzymes. Thromb. Haemost. (1998) 79:110–118.
  • ELG M, GUSTAFSSON D, CARLSSON S: Antithrombotic effects and bleeding time of thrombin inhibitors and warfarin in the rat. Thromb. Res. (1999) 94:187–197.
  • ELG M, GUSTAFSSON D, DEINUM J: The importance of enzyme inhibition kinetics for the effect of thrombin inhibitors in a rat model of arterial thrombosis. Thromb. Haemost. (1997) 78:1286–1292.
  • MEHTA JL, CHEN L, NICHOLS WW, MATTSSON C, GUSTAFSSON D, SALDEEN TG: Melagatran, an oral active-site inhibitor of thrombin, prevents or delays formation of electrically induced occlusive thrombus in the canine coronary artery. J. Cardiovasc. Phannacol (1998) 31:345–351.
  • MATTSSON C, BJORKMAN J-A, ULVINGE J-C: Melagatran, hirudin and heparin as adjuncts to tissue-type plasminogen activator in a canine model of coronary artery thrombosis. Fibrinolysis and Proteolysis (1997) 11:121–128.
  • BATES ER: Bivalirudin for percutaneous coronary intervention and in acute coronary syndromes. Curc Cardiol Rep (2001) 3:348–354.
  • PIANA RN, AHMED WH, CHAITMAN B et al.: Effect of transient abrupt vessel closure during otherwise successful angioplasty for unstable angina on clinical outcome at six months. Hirulog Angioplasty Study Investigators. J. Am .Coll .Cardiol (1999) 33:73–78.
  • BITTL JA: Comparative safety profiles of hirulog and heparin in patients undergoing coronary angioplasty. The Hirulog Angioplasty Study Investigators. Am. Heart. J. (1995) 130:658–665.
  • BASU S, LARSSON A, MATTSSON C et al.: Effects of melagatran, a novel direct thrombin inhibitor, during experimental septic shock. Expert Opin. Investig. Drugs (2000) 9:1129–1137.
  • BERNARD GR, VINCENT JL, LATERRE PF et al.: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl. I Med. (2001) 344:699–709.
  • •Reduced mortality by the administration of activated protein C in severe human sepsis.
  • ESMON CT: Introduction: are natural anticoagulants candidates for modulating the inflammatory response to endotwdn? Blood (2000) 95:1113–1116.
  • ZHAO K, ZHOU Y, LIN Z: Structure of basic phospholipase A2 from Agkistrodon halys Pallas: implications for its association, hemolytic and anticoagulant activities. Toxicon (2000) 38:901–916.
  • YOKOTA Y, HANASAKI K, ONO T, NAKAZATO H, KOBAYASHI T, ARITA H: Suppression of murine endotoxic shock by sPLA2 inhibitor, indoxam, through group IIA sPLA2-independent mechanisms. Biochim. Biophys. Acta. (1999) 1438:213–222.
  • BAEK SH, YUN SS, KWON TK, KIM JR, CHANG HW, KWAK JY, KIM JH, KWUN KB: The effects of two new antagonists of secretory PLA2 on TNF, iNOS, and COX-2 expression in activated macrophages. Shock (1999) 12:473–478.
  • BAUER KA, ERIKSSON BI, LASSEN MR, TURPIE AGG: Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. N Engl. J. Med. (2001) 345:1305–1310.
  • •Reduced incidence of venous thrombo-embolic events after the postoperative administration of fondaparinux versus preoperative enoxaparin in patients undergoing knee surgery.
  • ERIKSSON BI, BAUER KA, LASSEN MR, TURPIE AGG: Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. N Engl. J. Med (2001) 345:1298–1304.
  • COUSSEMENT PK, . BASSAND JP, BASSAND JP et al.: A synthetic factor-Xa inhibitor (0RG31540/5R9017A) as an adjunct to fibrinolysis in acute myocardial infarction. The PENTALYSE study. Euc Heart J. (2001) 22:1716–1724.

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.